Recent advances on smart glycoconjugate vaccines in infections and cancer.
Recent advances on smart glycoconjugate vaccines in infections and cancer.
复制标题
智能糖缀合物疫苗在感染和癌症方面的最新进展
DOI：
10.1111/febs.15909
复制
发表时间：
2022-07
期刊：
影响因子：
5.4
通讯作者：
van Vliet, Sandra J.
中科院分区：
文献类型：
--
作者：
Anderluh, Marko;Berti, Francesco;Bzducha-Wrobel, Anna;Chiodo, Fabrizio;Colombo, Cinzia;Compostella, Federica;Durlik, Katarzyna;Ferhati, Xhenti;Holmdahl, Rikard;Jovanovic, Dragana;Kaca, Wieslaw;Lay, Luigi;Marinovic-Cincovic, Milena;Marradi, Marco;Ozil, Musa;Polito, Laura;Reina, Jose Juan;Reis, Celso A.;Sackstein, Robert;Silipo, Alba;Svajger, Urban;Vanek, Ondrej;Yamamoto, Fumiichiro;Richichi, Barbara;van Vliet, Sandra J.
疫苗接种是生物医学研究中最伟大的成就之一，通过诱导病原体特异性体液和细胞免疫应答来预防许多传染病的死亡和发病。目前，没有有效的疫苗可用于具有高度可变抗原负荷的病原体，如人类免疫缺陷病毒或诱导细胞T细胞免疫以对抗癌症。最近的SARS-CoV-2爆发加强了设计智能治疗疫苗模式以确保公共健康的相关性。事实上，学术界和私营公司正在共同努力开发针对这种病毒的新型疫苗原型。许多病原体被致密的聚糖涂层覆盖，这形成了疫苗开发的有吸引力的目标。此外，许多肿瘤类型的特征在于改变的糖基化谱，其被称为“肿瘤相关碳水化合物抗原”。不幸的是，聚糖不会引起强烈的免疫应答，通常作为T细胞非依赖性抗原，不会引发保护性免疫球蛋白G应答，也不会诱导免疫记忆。糖化学家和糖免疫学家之间密切而持续的交流对于成功开发有效的免疫调节剂至关重要。很明显，这是发现新方法的关键点，这可以显着提高我们对免疫系统的理解。在这篇综述中，我们讨论了针对聚糖表位的疫苗开发的最新进展，以获得选择性免疫应答，并提供了不同的免疫原性构建体在提高糖疫苗效力中的作用的概述。本文综述了近年来合成糖缀合物疫苗在感染和癌症中的研究进展。我们提供了一个概述不同的免疫原性构建体在癌症和一些相关的细菌和病毒感染的免疫反应的调制中的作用，根据不同的载体的使用，针对的病理表位的多样性，以及向免疫系统的模式。
Vaccination is one of the greatest achievements in biomedical research preventing death and morbidity in many infectious diseases through the induction of pathogen‐specific humoral and cellular immune responses. Currently, no effective vaccines are available for pathogens with a highly variable antigenic load, such as the human immunodeficiency virus or to induce cellular T‐cell immunity in the fight against cancer. The recent SARS‐CoV‐2 outbreak has reinforced the relevance of designing smart therapeutic vaccine modalities to ensure public health. Indeed, academic and private companies have ongoing joint efforts to develop novel vaccine prototypes for this virus. Many pathogens are covered by a dense glycan‐coat, which form an attractive target for vaccine development. Moreover, many tumor types are characterized by altered glycosylation profiles that are known as “tumor‐associated carbohydrate antigens”. Unfortunately, glycans do not provoke a vigorous immune response and generally serve as T‐cell‐independent antigens, not eliciting protective immunoglobulin G responses nor inducing immunological memory. A close and continuous crosstalk between glycochemists and glycoimmunologists is essential for the successful development of efficient immune modulators. It is clear that this is a key point for the discovery of novel approaches, which could significantly improve our understanding of the immune system. In this review, we discuss the latest advancements in development of vaccines against glycan epitopes to gain selective immune responses and to provide an overview on the role of different immunogenic constructs in improving glycovaccine efficacy. In this review, the latest advancements in development of synthetic glycoconjugate vaccines in infection and cancer have been highlighted. We provide an overview on the role of different immunogenic constructs in the modulation of immune responses in cancer and in some relevant bacterial and viral infections according to the use of different carriers, the diversity of pathological epitopes targeted, and the mode of presentation to the immune system.
登录
查看更多内容
影响因子：
4.2
作者：
Wang, Qianli;Guo, Zhongwu
通讯作者：
Guo, Zhongwu
DOI：
10.1038/nrmicro.2017.173
发表时间：
2018-05
期刊：
Nature reviews. Microbiology
影响因子：
--
作者：
Belin BJ;Busset N;Giraud E;Molinaro A;Silipo A;Newman DK
通讯作者：
Newman DK
影响因子：
7.8
作者：
Avci FY;Li X;Tsuji M;Kasper DL
通讯作者：
Kasper DL
影响因子：
3.1
作者：
Amon, Ron;Reuven, Eliran Moshe;Padler-Karavani, Vered
通讯作者：
Padler-Karavani, Vered
影响因子：
15.3
作者：
Avery, OT;Goebel, WF
通讯作者：
Goebel, WF